https://www.fiercepharma.com/ a feed of the latest articles on our website en https://www.fiercepharma.com/manufacturing/lonza-expands-partnership-us-drugmaker-and-boosts-its-capacity-produce-adcs Contract manufacturing powerhouse Lonza is growing in more ways than one. The Swiss company revealed this week that it is expanding its capacity to manufacture antibody-drug conjugates—and that it has increased the scope of its partnership with a large, unnamed U.S. drugmaker. Jul 1, 2026 2:51pm Kevin Dunleavy https://www.fiercepharma.com/b0ec2912-ac19-4c21-9e84-4d6e711d28e2 https://www.fiercepharma.com/pharma/sanofi-unit-ireland-chided-fda-over-manufacturing-flubs-linked-altuviiio After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator. Jul 1, 2026 2:32pm Fraiser Kansteiner https://www.fiercepharma.com/f275152b-3d97-4d04-9703-b6989bc6f01d https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026-h2 In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. Jul 1, 2026 1:33pm Angus Liu, Kevin Dunleavy, Fraiser Kansteiner https://www.fiercepharma.com/a6f8f591-bb07-4a55-b9ca-16ca7271358a https://www.fiercepharma.com/pharma/bridgebio-attracts-1b-equity-financing-launches-attruby-potential-new-products As BridgeBio ramps up for the launch of three new medicines and continues to channel resources into its soon-to-be-blockbuster in ATTR-CM, Attruby, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in the California biotech. Jul 1, 2026 10:43am Kevin Dunleavy https://www.fiercepharma.com/96080b2f-d503-4499-a230-908225a37b9f https://www.fiercepharma.com/pharma/kimball-lays-out-103m-bolster-life-sci-cdmo-footprint-across-europe-india On a quest to bolster its life-sci contracting bona fides, self-described “multifaceted manufacturer” Kimball Electronics is going down the path of M&A. Jul 1, 2026 9:59am Fraiser Kansteiner https://www.fiercepharma.com/4627ee69-0a52-4bb6-bc3c-f46b77030afe https://www.fiercepharma.com/pharma/haleon-teams-microsoft-5-year-corporate-ai-deal-upgrade-consumer-health-operations Consumer health giant Haleon has tapped Microsoft to incorporate AI across its operations, joining a growing wave of healthcare and life sciences heavyweights turning to Big Tech to execute enterprise-wide digital overhauls. Jul 1, 2026 9:53am Angus Liu https://www.fiercepharma.com/5e9fdac7-31e4-4882-a99a-6d6c59a86bae https://www.fiercepharma.com/marketing/plus-therapeutics-rebrands-cerenome-it-deepens-ai-strategy Plus Therapeutics is evolving its business and has rebranded as Cerenome to reflect its expansion. Jul 1, 2026 2:50am Ben Adams https://www.fiercepharma.com/60715e3b-408e-472d-81aa-4c6d64f3d5f0 https://www.fiercepharma.com/pharma/fda-approves-orca-bio-cell-therapy-tregzi-blood-cancer-transplants Orca Bio has jumped into the commercial market with an FDA approval for Tregzi, a first-of-its-kind allogeneic regulatory T cell-based therapy for blood cancer patients requiring transplants.   Jul 1, 2026 12:16am Angus Liu https://www.fiercepharma.com/8ae05860-c40b-4e99-8f80-5bf7ed8c1b6b https://www.fiercepharma.com/pharma/astrazeneca-will-pay-34m-settle-free-nurses-kickback-lawsuit AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induce providers to write prescriptions for products paid for by Texas Medicaid. Jun 30, 2026 2:19pm Kevin Dunleavy https://www.fiercepharma.com/6943e28a-6852-4e88-85c8-616df6aa7d44 https://www.fiercepharma.com/marketing/rising-stars-how-novo-nordisks-tara-sparks-went-super-bowl-fan-super-bowl-marketer Tara Sparks was just days away from starting her new job at Novo Nordisk in February 2025 when she gathered with some friends to watch her team, the Philadelphia Eagles, take on reigning Super Bowl champs, the Kansas City Chiefs. Jun 30, 2026 2:21am Natalie Missakian https://www.fiercepharma.com/8880b092-fb8b-4b36-90e2-3bfb44427aa4 https://www.fiercepharma.com/pharma/medical-journal-retracts-tavneos-pivotal-study-article-complicating-amgens-defense-effort As Amgen’s rare disease medicine Tavneos comes under intensifying pressure from the FDA, the company faces a new hurdle with a leading medical journal’s retraction of the drug’s pivotal study data. Jun 30, 2026 10:48am Eric Sagonowsky https://www.fiercepharma.com/b6b4f1a1-173e-4e04-bac5-51a8f2b217ce https://www.fiercepharma.com/manufacturing/fda-selects-lilly-regeneron-fujifilm-and-4-others-precheck-pilot-program Eli Lilly, Regeneron and Fujifilm are among the seven companies that have been selected to participate in the FDA's PreCheck Pilot Program, designed to strengthen drug manufacturing and supply chain resilience in the U.S. The other participants are Amneal, Cellares, Kriya and Kyowa Kirin. Jun 30, 2026 9:32am Kevin Dunleavy https://www.fiercepharma.com/7da932c7-abfa-4fa0-8b82-d141423d70f3 https://www.fiercepharma.com/pharma/after-monotherapy-failure-abbvie-and-genmab-tout-epkinly-combo-win-dlbcl Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma, a positive phase 3 combination trial for AbbVie and Genmab’s Epkinly has renewed confidence ahead of its high-stakes first-line readout. Jun 30, 2026 9:55am Angus Liu https://www.fiercepharma.com/22361f8c-11d6-439a-a706-4b2fff9b316f https://www.fiercepharma.com/marketing/cmi-media-group-bridges-gaps-pharma-marketing-tech-newly-launched-ad-astra-platform CMI Media Group's Ad Astra platform looks to connect siloed pharma marketing technologies, with its initial focus targeting omnichannel orchestration. Jun 29, 2026 5:56pm Zoey Becker https://www.fiercepharma.com/bb14c67e-3cb0-4a75-82b1-345a9f23bd0d https://www.fiercepharma.com/manufacturing/unicycive-turned-away-fda-again-over-third-party-manufacturers-shortfalls Unicycive is optimistic the third-party manufacturing facility can meet FDA standards to support an approval, CEO Shalabh Gupta, M.D., said in a statement. Jun 30, 2026 8:41am Eric Sagonowsky https://www.fiercepharma.com/4f2a80a3-b7a9-49bc-af53-070a157379ec https://www.fiercepharma.com/marketing/klick-bags-oxford-pharmagenesis-3rd-takeover-18-months Klick Health has struck its third takeover in 18 months, snapping up Oxford PharmaGenesis to expand its global reach and deepen its scientific expertise. Jun 29, 2026 11:01am Nick Paul Taylor https://www.fiercepharma.com/7d3cae0f-0d38-438c-bd00-109b0a9008a0 https://www.fiercepharma.com/pharma/beone-brukinsa-hits-goal-mantle-cell-lymphoma-confirmatory-trial A Brukinsa regimen has delivered a large progression-free survival benefit in what BeOne Medicines called a “new chemotherapy-free standard” in first-line mantle cell lymphoma. Jun 29, 2026 4:09pm Angus Liu https://www.fiercepharma.com/6dab07c0-2a3d-467d-9748-78de1f597fa0 https://www.fiercepharma.com/pharma/zymeworks-acquires-struggling-theravance-929m Four months after Theravance Biopharma shut down its R&D unit, laid off half its staff and signaled it was up for sale, the Dublin-based company has entered into an agreement to be bought out by Zymeworks for $929 million plus a contingent value right. Jun 29, 2026 11:09am Kevin Dunleavy https://www.fiercepharma.com/6c47ace7-1667-4296-a6ae-2c8e8d9adf5c https://www.fiercepharma.com/manufacturing/fda-rejects-sobi-gout-drug-over-manufacturing-issues-sparing-amgen-blockbuster Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA. Jun 29, 2026 10:53am Angus Liu https://www.fiercepharma.com/a6f06946-b58e-443c-916a-f0a8cb6dba5d https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026 In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. Jan 2, 2026 8:07am Angus Liu, Eric Sagonowsky, Fraiser Kansteiner, Kevin Dunleavy, Zoey Becker https://www.fiercepharma.com/39cf200b-2bd0-4cd5-889a-1c71e8f5c4fd https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions. Apr 21, 2026 10:06am Angus Liu, Kevin Dunleavy, Fraiser Kansteiner https://www.fiercepharma.com/95fc1f29-4c60-4c4e-85a1-7e3739ee4672 https://www.fiercepharma.com/pharma/look-out-amgen-here-comes-viridian-fda-nod-ted-med-lumvoa The FDA has approved Viridian Therapeutics’ thyroid eye disease treatment, Lumvoa, initiating competition with Amgen’s blockbuster Tepezza, which is the only other therapy on the market for the eye-bulging autoimmune condition. Jun 29, 2026 8:31am Kevin Dunleavy https://www.fiercepharma.com/485c7cf7-d731-4f8f-9084-b1253df15db7 https://www.fiercepharma.com/sponsored/real-world-data-powers-next-gen-biopharma How high-fidelity real-world data is reshaping clinical development, precision medicine, and AI-driven innovation. Jun 22, 2026 9:37am Questex Partner https://www.fiercepharma.com/9c9ea00a-b625-4ff9-b57c-cb2fcc3fae0e https://www.fiercepharma.com/manufacturing/fda-slaps-dr-reddys-hyderabad-biologics-plant-seven-observations-new-form-483 The agency spotted seven observations at Dr. Reddy's Bachupally, Hyderabad, biologics plant following a mid-June inspection. Jun 26, 2026 11:07am Zoey Becker https://www.fiercepharma.com/a1a5e7d3-99a4-4aac-9058-dbfc8429fb27 https://www.fiercepharma.com/pharma/sanofi-subject-antitrust-probe-ec-kicks-formal-proceedings The European Commission has kicked off formal proceedings in an antitrust investigation against Sanofi. The probe surrounds the French drugmaker's marketing of its flu vaccine for at-risk seniors, Efluelda. Jun 26, 2026 11:04am Kevin Dunleavy https://www.fiercepharma.com/7d7a365e-4f65-4b1e-ae1d-8dc23ae76815